Aurealis Pharma to Present at Swiss Nordic Bio 2018 in Zurich, February 8th 2018
Basel Switzerland, Kuopio Finland – February 6th 2018.
Aurealis Pharma, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic inflammation and cancer, announced today that CEO Juha Yrjänheikki will attend and present the company´s progress at the Swiss Nordic Bio 2018 partnering and investor event in Zurich on February 8th 2018.
The presentation is scheduled for:
- Time: Thursday, February 8th 2018 at 10:55 am.
- Location: Renaissance Zurich Tower Hotel, Room: Bavaria B.
“We are looking forward to this intensive one day partnering and investor event. We will present and speak with investors and pharma about our chronic wound product AUP-16, which is in clinical trial application filing stage. We will also update the audience on our pre-clinical programs on cancer and osteoarthritis” said CEO Juha Yrjänheikki.
About Aurealis Pharma
Aurealis Pharma is a Basel, Switzerland and Kuopio, Finland based privately-held biopharmaceutical company focusing on developing broadly applicable proprietary technology to re-educate the distorted host immune microenvironment in chronic inflammation and cancer to its proper state. Company´s technology is based on safe food-grade lactic acid bacteria delivering multiple human therapeutic proteins in target tissue effectively, safely and economically to address the unmet medical need in chronic wounds and cancer.
About SWISS NORDIC BIO
Swiss Nordic Bio in Zurich is a high-level partnering and investor event where Swiss and Nordic biotech startups, pharmaceutical companies and investors meet. Swiss Nordic Bio carries 12 years of tradition, previously Swiss Scandinavian Bio-Business Seminar, and is organized by the Nordic countries in cooperation with Swiss partners.
For more information:
Juha Yrjänheikki, CEO
Tel: +358 45 8433550